文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

头孢西丁治疗重症患者头孢西丁敏感产ESBL肠杆菌感染的药代动力学、疗效与耐受性:一项回顾性单中心研究

Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study.
PubMed 文献 · Ann Intensive Care · 2022-09-30
一句话结论重症患者持续给予大剂量头孢西丁(中位6 g/日)方能在肾功能正常者中达到PK/PD目标,但治疗失败率63%、头孢霉素耐药出现率32%。

该回顾性单中心研究在大学医院内科ICU纳入41例头孢西丁敏感的产ESBL肠杆菌感染患者(肺炎35例,85%),主要目的为测定头孢西丁药代动力学。头孢西丁中位给药5天,中位日剂量6 g持续给药,83%患者(34例)在起病24小时后达到>5×MIC的目标血药浓度;标准剂量6 g/24 h对MIC 4–8 mg/L不足以达标,但严重肾功能损害和接受肾脏替代治疗者除外。治疗失败26例(63%),其中死亡12例(29%)、换用替代抗生素13例(32%)、同一ESBL-PE复发11例(27%);7例(17%)发生归因于头孢西丁的严重不良事件,13例(32%)出现同一肠杆菌的头孢霉素耐药,且与剂量不足相关。

要点

  • 41例头孢西丁敏感ESBL-PE感染重症患者中,中位日剂量6 g持续给药,34例(83%)在起病24小时后达到>5×MIC目标浓度。
  • 标准剂量6 g/24 h对MIC高达4–8 mg/L不足以达到PK/PD目标,严重肾功能损害和接受肾脏替代治疗者除外。
  • 治疗失败26例(63%):死亡12例(29%)、换用替代抗生素13例(32%)、同一ESBL-PE复发11例(27%)。
  • 13例(32%)出现同一肠杆菌的头孢霉素耐药,且与剂量不足相关;7例(17%)发生归因于头孢西丁的严重不良事件。
  • 头孢西丁血药浓度强烈依赖肾功能,肾功能状态、MIC测定和治疗药物监测可能有助于个体化治疗。

适用人群与场景

  • 大学医院内科ICU中表现为头孢西丁敏感产ESBL肠杆菌感染并接受头孢西丁治疗的患者,共41例,以ESBL-PE肺炎为主(35例,85%)。

诊断标准与关键阈值

  • 目标血清浓度为头孢西丁起病24小时后>5×最小抑菌浓度(MIC)。
  • 标准剂量6 g/24 h对MIC高达4–8 mg/L不足以达到PK/PD目标血清浓度,严重肾功能损害和接受肾脏替代治疗的患者除外。

处置流程与药物剂量

  • 头孢西丁采用持续给药,中位[IQR]日剂量6[6-6] g,中位[IQR]疗程5[4-7]天。
  • 头孢西丁血药浓度强烈依赖肾功能;肾功能状态、MIC测定和治疗药物监测可能有助于该场景下的治疗个体化。

研究设计与关键结果

  • 回顾性单中心研究,纳入41例头孢西丁敏感ESBL-PE感染重症患者,主要终点为头孢西丁药代动力学。
  • 头孢西丁中位[IQR]给药疗程5[4-7]天,中位[IQR]日剂量6[6-6] g持续给药,34例(83%)在起病24小时后达到>5×MIC目标血清浓度。
  • 标准剂量6 g/24 h对MIC高达4–8 mg/L不足以达到PK/PD目标血清浓度,严重肾功能损害和接受肾脏替代治疗者除外。
  • 治疗失败26例(63%),其中死亡12例(29%)、换用替代抗生素13例(32%)、同一ESBL-PE感染复发11例(27%)。
  • 归因于头孢西丁的严重不良事件7例(17%);同一肠杆菌的头孢霉素耐药出现13例(32%),且与剂量不足相关。

证据类型、等级与局限

  • 证据类型:回顾性单中心研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,肾功能正常的患者可能需要持续给予大剂量头孢西丁才能达到PK/PD目标。
  • 作者认为,肾功能状态、MIC测定和治疗药物监测可能有助于该场景下的治疗个体化。
  • 该研究中治疗失败率为63%,头孢西丁安全性良好,但观察到较高的头孢霉素耐药出现率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Cefoxitin is active against some extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-PE), but has not been evaluated so far in the intensive care unit (ICU) settings. Data upon its pharmacokinetics (PK), tolerance and efficacy in critical conditions are scanty. We performed a retrospective single-center study in a university hospital medical ICU, in subjects presenting with cefoxitin-susceptible ESBL-PE infection and treated with cefoxitin. The primary aim was to determine cefoxitin PK. Secondary endpoints were efficacy, tolerance, and emergence of cephamycin-resistance.

RESULTS: Forty-one patients were included in this study, mainly with ESBL-PE pneumonia (35 patients, 85%). Cefoxitin was administered during a median [interquartile range (IQR)] duration of 5 [4-7] days. Cefoxitin serum concentrations strongly depended on renal function. Target serum concentration (> 5 × minimum inhibitory concentration (MIC) 24 h after cefoxitin onset was obtained in 34 patients (83%), using a median [IQR] daily dose of 6 [6-6] g with continuous administration. The standard dosage of 6 g/24 h was not sufficient to achieve the PK/PD target serum concentration for MIC up to 4-8 mg/L, except in patients with severe renal impairment and those treated with renal replacement therapy. Treatment failure occurred in 26 cases (63%), among whom 12 patients (29%) died, 13 patients (32%) were switched to alternative antibiotic therapy and 11 patients (27%) presented with relapse of infection with the same ESBL-PE. Serious adverse events attributed to cefoxitin occurred in 7 patients (17%). Acquisition of cephamycin-resistance with the same Enterobacterales was identified in 13 patients (32%), and was associated with underdosage.

CONCLUSION: Continuous administration of large doses of cefoxitin appears necessary to achieve the PK/PD target in patients with normal renal function. Renal status, MIC determination and therapeutic drug monitoring may be useful for treatment individualization in this setting. The treatment failure rate was 63%. The cefoxitin safety profile was favorable, but we observed a high rate of cephamycin-resistance emergence.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Chabert P, Provoost J, Cohen S, et al. Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study. Ann Intensive Care. 2022. PMID: 36175707. doi:10.1186/s13613-022-01059-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。